The expression of a second adenocarcinoma differentiation marker, SFTPC, was significantly reduced by AdSLFN12 treatment in only one LUAD cell (HCC827), while AdSLFN12 significantly reduced HOPX mRNA levels in two LUAD cells (HCC827 and H23) with no significant changes in LUSC cells (Figure 2B–D). Here, SFTPC is linked to adenocarcinoma.